Drug intelligence / Profile preview

TBD-FcRN

Development stage: Preclinical
Lead developer: OroGen BioSciences
Modality: Small Molecules
Administration: Oral

Overview

TBD-FcRN is an oral small molecule inhibitor of the neonatal Fc receptor (FcRn) under preclinical development by Orogen Therapeutics (formerly OroGen BioSciences) for the treatment of various autoimmune diseases. By blocking the interaction between FcRn and immunoglobulin G (IgG), the drug prevents the recycling of IgG antibodies, leading to their rapid clearance and degradation. This mechanism is designed to reduce the levels of pathogenic autoantibodies that drive autoimmune and inflammatory conditions, offering an oral alternative to existing biologic FcRn-targeted therapies.

Other names: TBD-FcRn

Targets

FCGRT (Neonatal crystallizable fragment receptor)

Beyond the preview

Go deeper on TBD-FcRN.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TBD-FcRN.

Explore the full profile